Literature DB >> 23303340

Prostate cancer: ESMO Consensus Conference Guidelines 2012.

A Horwich1, J Hugosson, T de Reijke, T Wiegel, K Fizazi, V Kataja.   

Abstract

The first ESMO Consensus Conference on prostate cancer was held in Zurich, Switzerland, on 17-19 November 2011, with the participation of a multidisciplinary panel of leading professionals including experts in methodological aspects. Before the conference, the expert panel prepared clinically relevant questions about prostate cancer in four areas for discussion as follows: diagnosis and staging, management of early localized disease, management of advanced localized disease and systemic disease. All relevant scientific literature, as identified by the experts, was reviewed in advance. During the Consensus Conference, the panel developed recommendations for each specific question. The recommendations detailed here are based on an expert consensus after careful review of published data. All participants have approved this final update.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23303340     DOI: 10.1093/annonc/mds624

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  40 in total

Review 1.  Imaging of distant metastases of prostate cancer.

Authors:  Filippo Pesapane; Marcin Czarniecki; Matteo Basilio Suter; Baris Turkbey; Geert Villeirs
Journal:  Med Oncol       Date:  2018-09-14       Impact factor: 3.064

2.  Time management in radiation oncology: evaluation of time, attendance of medical staff, and resources during radiotherapy for prostate cancer: the DEGRO-QUIRO trial.

Authors:  L Keilholz; J Willner; H-J Thiel; N Zamboglou; H Sack; W Popp
Journal:  Strahlenther Onkol       Date:  2013-10-16       Impact factor: 3.621

3.  Rechallenge of docetaxel combined with epirubicin given on a weekly schedule in advanced castration-resistant prostate cancer patients previously exposed to docetaxel and abiraterone acetate: a single-institution experience.

Authors:  R Petrioli; G Roviello; A I Fiaschi; L Laera; Salvatora T Miano; G De Rubertis; G Barbanti; V Bianco; S Brozzetti; E Francini
Journal:  Med Oncol       Date:  2015-01-31       Impact factor: 3.064

4.  Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.

Authors:  Eugene D Kwon; Charles G Drake; Howard I Scher; Karim Fizazi; Alberto Bossi; Alfons J M van den Eertwegh; Michael Krainer; Nadine Houede; Ricardo Santos; Hakim Mahammedi; Siobhan Ng; Michele Maio; Fabio A Franke; Santhanam Sundar; Neeraj Agarwal; Andries M Bergman; Tudor E Ciuleanu; Ernesto Korbenfeld; Lisa Sengeløv; Steinbjorn Hansen; Christopher Logothetis; Tomasz M Beer; M Brent McHenry; Paul Gagnier; David Liu; Winald R Gerritsen
Journal:  Lancet Oncol       Date:  2014-05-13       Impact factor: 41.316

5.  Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.

Authors:  Maha Hussain; Karim Fizazi; Fred Saad; Per Rathenborg; Neal Shore; Ubirajara Ferreira; Petro Ivashchenko; Eren Demirhan; Katharina Modelska; Andrew Krivoshik; Cora N Sternberg
Journal:  N Engl J Med       Date:  2018-06-28       Impact factor: 91.245

6.  Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5.

Authors:  Karim Fizazi; Robert Jones; Stephane Oudard; Eleni Efstathiou; Fred Saad; Ronald de Wit; Johann De Bono; Felipe Melo Cruz; George Fountzilas; Albertas Ulys; Flavio Carcano; Neeraj Agarwal; David Agus; Joaquim Bellmunt; Daniel P Petrylak; Shih-Yuan Lee; Iain J Webb; Bindu Tejura; Niels Borgstein; Robert Dreicer
Journal:  J Clin Oncol       Date:  2015-01-26       Impact factor: 44.544

7.  Guidelines should be assessed based on the underlying evidence.

Authors:  Peter R Carroll; J Kellogg Parsons
Journal:  CMAJ       Date:  2019-08-06       Impact factor: 8.262

Review 8.  Prostate-specific kallikrein-related peptidases and their relation to prostate cancer biology and detection. Established relevance and emerging roles.

Authors:  Daniel L J Thorek; Michael J Evans; Sigrid V Carlsson; David Ulmert; Hans Lilja
Journal:  Thromb Haemost       Date:  2013-08-01       Impact factor: 5.249

9.  Differences of the immune cell landscape between normal and tumor tissue in human prostate.

Authors:  E Zhang; F Dai; Y Mao; W He; F Liu; W Ma; Y Qiao
Journal:  Clin Transl Oncol       Date:  2019-05-10       Impact factor: 3.405

10.  Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study.

Authors:  Yohann Loriot; Karim Fizazi; Robert J Jones; Jan Van den Brande; Rhoda L Molife; Aurelius Omlin; Nicholas D James; Edwina Baskin-Bey; Marten Heeringa; Benoit Baron; Gertjan M Holtkamp; Taoufik Ouatas; Johann S De Bono
Journal:  Invest New Drugs       Date:  2014-04-27       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.